• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C ...

    Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus

  2. Veloxis announces that it has filed an action against the Food and Drug Administration , seeking an order requiring FDA to grant final approval to Envarsus® XR

    Veloxis announces that it has filed an action against the Food and Drug Administration , seeking an order requiring FDA to grant final approval to Envarsus® XR

  3. Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

    Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

  4. Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)

    Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)

  5. FDA approves AbbVie's hepatitis treatment

    FDA approves AbbVie's hepatitis treatment

  6. AstraZeneca Gets FDA Approval for Ovarian Cancer Drug

    AstraZeneca Gets FDA Approval for Ovarian Cancer Drug

  7. AstraZeneca Gets FDA Approval for Ovarian Cancer Drug

    AstraZeneca Gets FDA Approval for Ovarian Cancer Drug

  8. Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I

    Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I

  9. Veloxis Comments on U.S. District Court Order

    Veloxis Comments on U.S. District Court Order

  10. Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy

    Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.